Business EconomyPosted at: Oct 1 2026 11:32PM


Acrotech Biopharma launches ADQUEY in US, enters dermatology market

Hyderabad, Sep 30 (UNI) Acrotech Biopharma Inc, , a subsidiary of Hyderabad based Aurobindo Pharma, on Thursday announced the launch of ADQUEY (difamilast 1%) ointment in the US for the treatment of mild-to-moderate atopic dermatitis in adults and children aged two years and above.
The non-steroidal topical phosphodiesterase 4 (PDE4) inhibitor is intended for patients with atopic dermatitis, a chronic inflammatory skin condition, the pharma company said in a release.
The product was originally discovered and developed by Otsuka Pharmaceutical Co Ltd and licensed to Acrotech Biopharma for commercialisation in the US.
The launch marks Acrotech's entry into the US dermatology market.
The company has also established a dedicated dermatology business unit with specialised marketing, sales and field-based capabilities to support healthcare professionals and improve patient access to treatment.
According to IQVIA data cited by the company, the US market for atopic dermatitis treatments was estimated at around USD 1.3 billion for the 12 months ending July 2026.
"The launch of ADQUEY is an important milestone for Acrotech and marks our entry into the US dermatology market with a differentiated treatment option for patients living with atopic dermatitis," said Ashish Anvekar, President of Acrotech Biopharma.
He said the company was building a dedicated dermatology platform to support the product's launch and pursue further opportunities to address unmet needs in dermatological care.
The new business unit will focus on raising awareness of ADQUEY, engaging with dermatology healthcare professionals and supporting patients throughout their treatment journey, while developing capabilities to expand the company's presence in the specialty dermatology market.
The launch is part of Acrotech's strategy to expand its portfolio of proprietary medicines and establish specialised commercial platforms in therapeutic areas with significant patient needs.
UNI KNR RN
Tags: #Acrotech Biopharma launches ADQUEY in US# enters dermatology market
More News

Anil Reddy Vennum unanimously elected AIPMA president

01 Oct 2026 | 11:16 PM

Hyderabad/Mumbai, Oct 1 (UNI) Hyderabad-based industrialist Anil Reddy Vennum has been unanimously elected President of the All India Plastics Manufacturers Association (AIPMA) for a one-year term, becoming the first Telugu person to head the 81-year-old national trade body.

see more..

01 Oct 2026 | 11:13 PM

Hyderabad, Oct 1 (UNI) The Singareni Collieries Company Limited (SCCL) has registered a 4 per cent growth in coal transportation during the first half of the current financial year, transporting 299.4 lakh tonnes of coal against 287.6 lakh tonnes during the corresponding period last year.

see more..

AP: GCC steps up efforts to secure global recognition for Araku coffee

01 Oct 2026 | 11:04 PM

Visakhapatnam, Oct 1 (UNI) The Girijan Cooperative Corporation (GCC) is intensifying efforts to secure international recognition for Araku coffee and improve market opportunities and incomes for tribal farmers, GCC Chairman Kidari Sravan Kumar said today.

see more..

RSP New Plate Mill sets new production, dispatch records in September

01 Oct 2026 | 9:04 PM

Bhubaneswar, Oct 1 (UNI) The New Plate Mill (NPM) of Rourkela Steel Plant (RSP) has achieved its highest-ever September production and dispatch, setting new performance records during September 2026, RSP sources said on Thursday.

see more..

Tata Sons Board unlikely to clear Noel Tata's proposal to restructure holding company

01 Oct 2026 | 8:27 PM

Mumbai, Oct 1 (UNI) The Tata Sons board is unlikely to clear a proposal sent by Tata Trusts Chairman Noel Tata to the board to consider and approve a strategic reorganisation which would take Tata Sons outside the regulatory framework which triggered off the RBI’s directive to list the holding company on the stock exchange, sources said here today.

see more..